Today, Somersault Snack Co., LLC, in cooperation with the U.S. Food and Drug Administration (FDA) is voluntarily recalling all packages of Somersaults Cinnamon Crunch products with Sell By Dates of 8/30/2013 or earlier. The packaging of these products inadvertently fails to declare the allergen milk which is contained in a flavoring ingredient of these products.
Southwest Ice Cream Specialties Conducts Voluntary Recall of ShurFine® Brand “Creamery Select Premium Ice Cream Dulce de Leche” 1.75 Quarts Ice Cream Because Package May Contain Praline Pecan Ice Cream Which May Contain Undeclared Allergens (Wheat, Soy and Pecans)
McKinney, Texas (January 3, 2012) – Southwest Ice Cream Specialties is voluntarily recalling ShurFine Brand “Creamery Select (Premium Ice Cream) Dulce de Leche” Ice Cream (1.75 quarts, 1.66L) because it may contain praline pecan ice cream, which contains wheat, soy and pecans. The product is packed with a ShurFine Praline Pecan lid, but bears the Dulce de Leche product labeling on the carton. While no ShurFine product has been linked to any illness related to allergens at this time, Southwest Ice Cream Specialties is taking this precautionary measure because the ice cream inside the carton contains pecans, soy and wheat that are not declared on the packaging.
ANDY CAPP’S HOT FRIES RECALLED DUE TO UNDECLARED SOY ALLERGEN
Today, ConAgra Foods, Omaha, Neb., in cooperation with the U.S. Food and Drug Administration (FDA) is voluntarily recalling a limited number of packages of its Andy Capp’s Hot Fries flavor product that may contain the Andy Capp’s Cheddar Fries flavor, and, therefore, an undeclared allergen—soy. People who have an allergy or severe sensitivity to soy run the risk of serious or life-threatening allergic reaction if they consume these products. There have been no illnesses reported to date in connection with this product.
FDA proposes new food safety standards for foodborne illness prevention and produce safety
The U.S. Food and Drug Administration today proposed two new food safety rules that will help prevent foodborne illness. The proposed rules implement the landmark, bipartisan FDA Food Safety Modernization Act (FSMA) and are available for public comment for the next 120 days. The FDA encourages Americans to review and comment on these important proposed rules.
Gilster-Mary Lee Corp. Issues Allergy Alert on Undeclared Tree Nuts in Food Club Chocolate Chunk Brownie Mix.
Gilster-Mary Lee of Chester, Illinois is voluntarily recalling one lot of Chocolate Chunk Brownie Mix because it contains cartons containing undeclared walnuts. (Wrong packaging/cartons were used that do not declare walnuts).
Allergy Alert – Undeclared Eggs in Kinnikinnick Foods Frozen Pie Crust
Kinnikinnick Foods of 10940 120 street, Edmonton, AB is warning consumers with Egg Allergies not to consume Kinnikinnick Frozen Pie Crust because it contains EGG products which may not be indicated on an applied ingredient label. Products without an ingredient label applied to the box are not subject to this recall as they correctly list the product as containing eggs.
FDA approves first anti-diarrheal drug for HIV/AIDS patients
The U.S. Food and Drug Administration today approved Fulyzaq (crofelemer) to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy, a combination of medicines used to treat HIV infection.
Procesadora de Productos Marinos Delifish S.A. Recalls Product Because Of Possible Listeria Monocytogenes Risk
Potential Listeria-positive products have been identified and we can confirm that Delifish S.A.
has issued a voluntary recall of cold smoked salmon products potentially containing Listeria
monocytogenes placed on the market in the USA produced from lots 249 through 291,
manufactured between September 5 2012 and October 17, 2012.
FDA approves first drug to treat multi-drug resistant tuberculosis
On Dec. 28, the U.S. Food and Drug Administration approved Sirturo (bedaquiline) as part of combination therapy to treat adults with multi-drug resistant pulmonary tuberculosis (TB) when other alternatives are not available.
FDA approves Eliquis to reduce the risk of stroke, blood clots in patients with non-valvular atrial fibrillation
The U.S. Food and Drug Administration today approved the anti-clotting drug Eliquis (apixaban), an oral tablet used to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem.